Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736397 · ClinicalTrials.gov registry record · Phase 2
Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis
A Phase 2 study, sponsored by Keryx Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT01736397 is a Phase 2 study that has completed, run by Keryx Biopharmaceuticals. The registered enrollment target is 149 participants.
The verdict
NCT01736397, a Phase 2 study, has completed, sponsored by Keryx Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if KRX-0502 (ferric citrate) is a safe and effective treatment for the management of serum phosphorus levels and iron deficiency in anemic chronic kidney disease (CKD) stage 3-5 subjects not on dialysis. Total length of treatment is approximately 12 weeks.
Interventions
- DRUG Placebo
- DRUG Ferric Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736397
The ClinicalTrials.gov registry entry for NCT01736397 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keryx Biopharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01736397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736397 about?
NCT01736397 is a clinical study titled "Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis". The purpose of this study is to determine if KRX-0502 (ferric citrate) is a safe and effective treatment for the management of serum phosphorus levels and iron deficiency in anemic chronic kidney disease (CKD) stage 3-5 subjects not on dialysis. Total length of treatment is approximately 12 weeks.
What is the current status of trial NCT01736397?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2012-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01736397?
The interventions under investigation include: Placebo (DRUG), Ferric Citrate (DRUG).
Who is sponsoring clinical trial NCT01736397?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.